Arbutus to Announce Q2 2024 Financial Results and Corporate Update

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical entity specializing in advanced virology, revealed plans to disclose its second quarter 2024 financial results and provide a corporate update on August 1, 2024. The press release will be issued at 7:30 a.m. ET, followed by a conference call and webcast at 8:45 a.m. ET on the same day. Participants can register for the call through a provided link, and the live webcast will be accessible via the Investors section on Arbutus' website, with an archived version available afterward.

Arbutus Biopharma, listed on Nasdaq under the ticker ABUS, focuses on developing innovative treatments for chronic hepatitis B virus (cHBV) infections. The company aims to create a functional cure by combining therapies that suppress HBV DNA, lower surface antigen levels, and augment HBV-specific immune responses.

The company's research pipeline features proprietary compounds, including imdusiran (AB-729), an RNA interference (RNAi) therapeutic, and AB-101, an oral PD-L1 inhibitor. Imdusiran has shown significant clinical results by reducing surface antigen and reactivating the HBV-specific immune response. It is undergoing three Phase 2a combination clinical trials. Meanwhile, AB-101 is in the early stages of clinical evaluation, specifically Phase 1a/1b trials.

Arbutus leverages its extensive expertise in virology to develop these novel therapeutics, aiming to offer a functional cure for those affected by chronic hepatitis B. For additional information on the company's activities and developments, visitors can explore their official website.